Illinois 2023-2024 Regular Session

Illinois House Bill HB3490 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3490 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED: New Act Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2023, and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act. LRB103 27325 CPF 53696 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3490 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED: New Act New Act Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2023, and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act. LRB103 27325 CPF 53696 b LRB103 27325 CPF 53696 b A BILL FOR
2	2	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3490 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED:
3	3	New Act New Act
4	4	New Act
5	5	Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2023, and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act.
6	6	LRB103 27325 CPF 53696 b LRB103 27325 CPF 53696 b
7	7	LRB103 27325 CPF 53696 b
8	8	A BILL FOR
9	9	HB3490LRB103 27325 CPF 53696 b HB3490 LRB103 27325 CPF 53696 b
10	10	HB3490 LRB103 27325 CPF 53696 b
11	11	1 AN ACT concerning health.
12	12	2 Be it enacted by the People of the State of Illinois,
13	13	3 represented in the General Assembly:
14	14	4 Section 1. Short title. This Act may be cited as the
15	15	5 Canadian Prescription Drug Importation Act.
16	16	6 Section 5. Legislative findings. The General Assembly
17	17	7 finds:
18	18	8 (1) United States consumers pay some of the highest
19	19	9 prescription drug prices in the world, and it is estimated
20	20	10 that United States consumers pay twice as much as the amount
21	21	11 Canadian consumers pay for patented prescription drugs and 20%
22	22	12 more for generic drugs.
23	23	13 (2) Federal law, as codified in 21 U.S.C. 384, authorizes
24	24	14 the Secretary of the United States Department of Health and
25	25	15 Human Services to allow wholesale importation of prescription
26	26	16 drugs from Canada if such importation is shown to be both safe
27	27	17 and less costly for United States consumers.
28	28	18 (3) Although importing prescription drugs would be less
29	29	19 costly, there may be risks posed to consumer health and safety
30	30	20 if the source, quality, and purity of prescription drugs sold
31	31	21 by online pharmacies cannot be verified.
32	32	22 (4) Canada has a rigorous regulatory system to license
33	33	23 prescription drugs, equivalent to the licensing system in the
34	34
35	35
36	36
37	37	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3490 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED:
38	38	New Act New Act
39	39	New Act
40	40	Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2023, and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act.
41	41	LRB103 27325 CPF 53696 b LRB103 27325 CPF 53696 b
42	42	LRB103 27325 CPF 53696 b
43	43	A BILL FOR
44	44
45	45
46	46
47	47
48	48
49	49	New Act
50	50
51	51
52	52
53	53	LRB103 27325 CPF 53696 b
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63	HB3490 LRB103 27325 CPF 53696 b
64	64
65	65
66	66	HB3490- 2 -LRB103 27325 CPF 53696 b HB3490 - 2 - LRB103 27325 CPF 53696 b
67	67	HB3490 - 2 - LRB103 27325 CPF 53696 b
68	68	1 United States.
69	69	2 (5) In the United States, Title II of the federal Drug
70	70	3 Quality and Security Act, referred to as the Drug Supply Chain
71	71	4 Security Act, has significantly improved drug security and
72	72	5 safety through a system of pharmaceutical product
73	73	6 track-and-trace procedures.
74	74	7 (6) A wholesale drug importation program for the exclusive
75	75	8 benefit of residents of the State should be designed and
76	76	9 implemented to provide consumers of the State access to safe
77	77	10 and less expensive prescription drugs.
78	78	11 Section 10. Definitions. As used in this Act:
79	79	12 "Canadian supplier means a manufacturer, wholesale
80	80	13 distributor, or pharmacy that is appropriately licensed or
81	81	14 permitted under Canadian federal and provincial laws and
82	82	15 regulations to manufacturer, distribute, or dispense
83	83	16 prescription drugs.
84	84	17 "Department" means the Department of Public Health.
85	85	18 "Drug" or prescription drug" has has the same meaning as
86	86	19 "drugs" in Section 1 of the Pharmacy Practice Act.
87	87	20 "Eligible importer" means an importer that is:
88	88	21 (1) a pharmacist or wholesaler employed by or under
89	89	22 contract with a medicaid pharmacy, for dispensing to the
90	90	23 pharmacy's medicaid recipients;
91	91	24 (2) a pharmacist or wholesaler employed by or under
92	92	25 contract with the Department of Corrections, for
93	93
94	94
95	95
96	96
97	97
98	98	HB3490 - 2 - LRB103 27325 CPF 53696 b
99	99
100	100
101	101	HB3490- 3 -LRB103 27325 CPF 53696 b HB3490 - 3 - LRB103 27325 CPF 53696 b
102	102	HB3490 - 3 - LRB103 27325 CPF 53696 b
103	103	1 dispensing to inmates in the custody of the Department of
104	104	2 Corrections;
105	105	3 (3) a commercial plan, as defined by rules adopted by
106	106	4 the Department and as approved by the federal government;
107	107	5 and
108	108	6 (4) a licensed pharmacist under the Pharmacy Practice
109	109	7 Act or registered wholesaler approved by the Department.
110	110	8 "Federal act" means the federal Food, Drug, and Cosmetic
111	111	9 Act.
112	112	10 "Medicaid pharmacy means a pharmacy licensed under the
113	113	11 Pharmacy Practice Act that has a Medicaid provider agreement
114	114	12 in effect with the State and is in good standing with the
115	115	13 State.
116	116	14 "Pharmacist" means a person who holds and active and
117	117	15 unencumbered license to practice pharmacy under the Pharmacy
118	118	16 Practice Act.
119	119	17 "Program" means the Canadian prescription drug importation
120	120	18 program created in this Act.
121	121	19 "Vendor" means a vendor with which the State who contracts
122	122	20 for the provision of services under the program pursuant to
123	123	21 subsection (a) of Section 15.
124	124	22 Section 15. Canadian prescription drug importation
125	125	23 program; importation process; contract with vendor; vendor
126	126	24 duties.
127	127	25 (a) The Canadian prescription drug importation program is
128	128
129	129
130	130
131	131
132	132
133	133	HB3490 - 3 - LRB103 27325 CPF 53696 b
134	134
135	135
136	136	HB3490- 4 -LRB103 27325 CPF 53696 b HB3490 - 4 - LRB103 27325 CPF 53696 b
137	137	HB3490 - 4 - LRB103 27325 CPF 53696 b
138	138	1 created in the Department. Upon receiving approval of the
139	139	2 program as described in Section 25, the Department shall
140	140	3 contract with one or more vendors to provide services under
141	141	4 the program. For 3 years following the effective date of this
142	142	5 Act, the selection of any vendor pursuant to this subsection
143	143	6 is exempt from the requirements of the Illinois Procurement
144	144	7 Code.
145	145	8 (b) Each vendor, in consultation with the Department and
146	146	9 any other vendors, shall establish a wholesale prescription
147	147	10 drug importation list that identifies the prescription drugs
148	148	11 that have the highest potential for cost savings to the State.
149	149	12 In developing the list, each vendor shall consider, at a
150	150	13 minimum, which prescription drugs will provide the greatest
151	151	14 cost savings to the State, including prescription drugs for
152	152	15 which there are shortages, specialty prescription drugs, and
153	153	16 high-volume prescription drugs. Each vendor shall revise the
154	154	17 list at least annually and at the direction of the State
155	155	18 department pursuant to this subsection. The Department shall
156	156	19 review the wholesale prescription drug importation list at
157	157	20 least every 3 months to ensure that it continues to meet the
158	158	21 requirements of the program. The Department may direct a
159	159	22 vendor to revise the list, as necessary. Each vendor, in
160	160	23 consultation with the Department, shall identify Canadian
161	161	24 suppliers who are in full compliance with relevant Canadian
162	162	25 federal and provincial laws and regulations and who have
163	163	26 agreed to export prescription drugs identified on the
164	164
165	165
166	166
167	167
168	168
169	169	HB3490 - 4 - LRB103 27325 CPF 53696 b
170	170
171	171
172	172	HB3490- 5 -LRB103 27325 CPF 53696 b HB3490 - 5 - LRB103 27325 CPF 53696 b
173	173	HB3490 - 5 - LRB103 27325 CPF 53696 b
174	174	1 wholesale prescription drug importation list. Each vendor
175	175	2 shall verify that such Canadian suppliers meet all of the
176	176	3 requirements of the program and will export prescription drugs
177	177	4 at prices that will provide cost savings to the State. Each
178	178	5 vendor shall contract with such eligible Canadian suppliers,
179	179	6 or facilitate contracts between eligible importers and
180	180	7 Canadian suppliers, to import prescription drugs under the
181	181	8 program. Each vendor shall assist the Department in developing
182	182	9 and administering a distribution program within the program.
183	183	10 Each vendor shall assist the Department with the annual report
184	184	11 described in this Act and provide any information requested by
185	185	12 the Department for the report. Each vendor shall ensure the
186	186	13 safety and quality of drugs imported under the program, as
187	187	14 follows:
188	188	15 (1) for an initial imported shipment, ensure that each
189	189	16 batch of the drug in the shipment is statistically sampled
190	190	17 and tested for authenticity and degradation in a manner
191	191	18 consistent with the federal act, and for any subsequent
192	192	19 imported shipment, ensure that a statistically valid
193	193	20 sample of the shipment is tested for authenticity and
194	194	21 degradation in a manner consistent with the federal act;
195	195	22 (2) certify that each drug: (i) is approved for
196	196	23 marketing in the United States and is not adulterated or
197	197	24 misbranded; and (ii) meets all of the labeling
198	198	25 requirements under 21 U.S.C. 352;
199	199	26 (3) maintain qualified laboratory records, including
200	200
201	201
202	202
203	203
204	204
205	205	HB3490 - 5 - LRB103 27325 CPF 53696 b
206	206
207	207
208	208	HB3490- 6 -LRB103 27325 CPF 53696 b HB3490 - 6 - LRB103 27325 CPF 53696 b
209	209	HB3490 - 6 - LRB103 27325 CPF 53696 b
210	210	1 complete data derived from all tests necessary to ensure
211	211	2 that the drug is in compliance with the requirements of
212	212	3 this Section; and
213	213	4 (4) maintain documentation demonstrating that the
214	214	5 testing required by this Section was conducted at a
215	215	6 qualified laboratory in accordance with the Federal Act
216	216	7 and any other applicable federal and State laws and
217	217	8 regulations governing laboratory qualifications.
218	218	9 (c) All testing required by this section must be conducted
219	219	10 in a qualified laboratory that meets the standards under the
220	220	11 Federal Act and any other applicable federal and State laws
221	221	12 and regulations governing laboratory qualifications for drug
222	222	13 testing.
223	223	14 (d) Each vendor shall maintain a list of all eligible
224	224	15 importers that participate in the program.
225	225	16 (e) Each vendor shall ensure compliance with Title II of
226	226	17 the federal Drug Quality and Security Act by all Canadian
227	227	18 suppliers, eligible importers, distributors, and other
228	228	19 participants in the program.
229	229	20 (f) Each vendor shall provide an annual financial audit of
230	230	21 its operations to the Department. Each vendor shall also
231	231	22 provide quarterly financial reports specific to the program
232	232	23 and shall include information concerning the performance of
233	233	24 its subcontractors and vendors. The Department shall determine
234	234	25 the format and contents of the reports.
235	235	26 (g) Each vendor shall submit evidence of a surety bond
236	236
237	237
238	238
239	239
240	240
241	241	HB3490 - 6 - LRB103 27325 CPF 53696 b
242	242
243	243
244	244	HB3490- 7 -LRB103 27325 CPF 53696 b HB3490 - 7 - LRB103 27325 CPF 53696 b
245	245	HB3490 - 7 - LRB103 27325 CPF 53696 b
246	246	1 with any bid or initial contract negotiation documents and
247	247	2 shall maintain documentation of evidence of such a bond with
248	248	3 the Department throughout the contract term. The surety bond
249	249	4 may be from this State or any other State in the United States
250	250	5 and must be in an amount of at least $25,000. The surety bond
251	251	6 or comparable security arrangement must include the State as a
252	252	7 beneficiary. In lieu of the surety bond, a vendor may provide a
253	253	8 comparable security agreement, such as an irrevocable letter
254	254	9 of credit or a deposit into a trust account or financial
255	255	10 institution that includes the State as a beneficiary, payable
256	256	11 to the State. The purposes of the bond or other security
257	257	12 arrangement are to:
258	258	13 (1) ensure participation of the vendor in any civil or
259	259	14 criminal legal action by the State department, any other
260	260	15 State agency, or private individuals or entities against
261	261	16 the vendor because of the vendor's failure to perform
262	262	17 under the contract, including, but not limited to, causes
263	263	18 of actions for personal injury, negligence, and wrongful
264	264	19 death;
265	265	20 (2) ensure payment by the vendor through the use of a
266	266	21 bond or other comparable security arrangement of any legal
267	267	22 judgments and claims that are awarded to the State, other
268	268	23 entities acting on behalf of the State, individuals, or
269	269	24 organizations if the vendor is assessed a final judgment
270	270	25 or other monetary penalty in a court of law for a civil or
271	271	26 criminal action under the program. The bond or comparable
272	272
273	273
274	274
275	275
276	276
277	277	HB3490 - 7 - LRB103 27325 CPF 53696 b
278	278
279	279
280	280	HB3490- 8 -LRB103 27325 CPF 53696 b HB3490 - 8 - LRB103 27325 CPF 53696 b
281	281	HB3490 - 8 - LRB103 27325 CPF 53696 b
282	282	1 security arrangement may be accessed if the vendor fails
283	283	2 to pay any judgment or claim within 60 days after final
284	284	3 judgment; and
285	285	4 (3) allow for civil and criminal litigation claims to
286	286	5 be made against the bond or other comparable security
287	287	6 arrangements for up to one year after the vendor's
288	288	7 contract under the program has ended with the Department,
289	289	8 the vendor's license is no longer valid, or the program
290	290	9 has ended, whichever occurs last.
291	291	10 (8) Each vendor shall maintain information and
292	292	11 documentation submitted under this Section for a period of at
293	293	12 least 7 years.
294	294	13 (9) The Department may require each vendor to collect any
295	295	14 other information necessary to ensure the protection of the
296	296	15 public health.
297	297	16 Section 20. Eligible prescription drugs; eligible Canadian
298	298	17 suppliers; eligible importers; distribution requirements.
299	299	18 (a) An eligible importer may import a prescription drug
300	300	19 from a Canadian supplier if:
301	301	20 (1) the drug meets the United States Food and Drug
302	302	21 Administration's standards related to safety,
303	303	22 effectiveness, misbranding, and adulteration;
304	304	23 (2) importing the drug would not violate federal
305	305	24 patent laws;
306	306	25 (3) importing the drug is expected to generate cost
307	307
308	308
309	309
310	310
311	311
312	312	HB3490 - 8 - LRB103 27325 CPF 53696 b
313	313
314	314
315	315	HB3490- 9 -LRB103 27325 CPF 53696 b HB3490 - 9 - LRB103 27325 CPF 53696 b
316	316	HB3490 - 9 - LRB103 27325 CPF 53696 b
317	317	1 savings; and
318	318	2 (4) the drug is not:
319	319	3 (i) a controlled substance as defined in 21 U.S.C.
320	320	4 802;
321	321	5 (ii) a biological product as defined in 42 U.S.C.
322	322	6 262;
323	323	7 (iii) an infused drug;
324	324	8 (iv) an intravenously injected drug;
325	325	9 (v) a drug that is inhaled during surgery; or
326	326	10 (vi) a drug that is a parenteral drug, the
327	327	11 importation of which is determined by the United
328	328	12 States Secretary of Health and Human Services to pose
329	329	13 a threat to the public health.
330	330	14 (b) A Canadian supplier may export prescription drugs into
331	331	15 the State under the program if the supplier:
332	332	16 (1) is in full compliance with relevant Canadian
333	333	17 federal and provincial laws and regulations;
334	334	18 (2) is identified by the vendor as eligible to
335	335	19 participate in the program; and
336	336	20 (3) submits an attestation that the supplier has a
337	337	21 registered agent in the United States, including the name
338	338	22 and United States address of the registered agent.
339	339	23 (c) The following entities are eligible importers and may
340	340	24 obtain imported prescription drugs:
341	341	25 (1) a pharmacist or wholesaler employed by or under
342	342	26 contract with a Medicaid pharmacy, for dispensing to the
343	343
344	344
345	345
346	346
347	347
348	348	HB3490 - 9 - LRB103 27325 CPF 53696 b
349	349
350	350
351	351	HB3490- 10 -LRB103 27325 CPF 53696 b HB3490 - 10 - LRB103 27325 CPF 53696 b
352	352	HB3490 - 10 - LRB103 27325 CPF 53696 b
353	353	1 pharmacy's Medicaid recipients;
354	354	2 (2) a pharmacist or wholesaler employed by or under
355	355	3 contract with the Department of Corrections, for
356	356	4 dispensing to inmates in the custody of the Department of
357	357	5 Corrections;
358	358	6 (3) commercial plans, as defined by rules promulgated
359	359	7 by the State Board and as approved by the federal
360	360	8 government; and
361	361	9 (4) a licensed pharmacist or wholesaler approved by
362	362	10 the Department under the Pharmacy Practice Act.
363	363	11 (d) The Department shall designate an office or division
364	364	12 that must be a licensed pharmaceutical wholesaler or that
365	365	13 shall contract with a licensed pharmaceutical wholesaler
366	366	14 licensed pursuant to Part 3 of Article 42.5 of Title 12. The
367	367	15 office or division designated by the Department shall:
368	368	16 (1) set a maximum profit margin so that a wholesaler,
369	369	17 distributor, pharmacy, or other licensed provider
370	370	18 participating in the program maintains a profit margin
371	371	19 that is no greater than the profit margin that the
372	372	20 wholesaler, distributor, pharmacy, or other licensed
373	373	21 provider whole have earned on the equivalent nonimported
374	374	22 drug;
375	375	23 (2) exclude generic products if the importation of the
376	376	24 products would violate United States patent laws
377	377	25 applicable to United States-branded products;
378	378	26 (3) comply with the requirements of 21 U.S.C. 360eee
379	379
380	380
381	381
382	382
383	383
384	384	HB3490 - 10 - LRB103 27325 CPF 53696 b
385	385
386	386
387	387	HB3490- 11 -LRB103 27325 CPF 53696 b HB3490 - 11 - LRB103 27325 CPF 53696 b
388	388	HB3490 - 11 - LRB103 27325 CPF 53696 b
389	389	1 through 360eee-4 as enacted in Title II of the federal
390	390	2 Drug Quality and Security Act; and
391	391	3 (4) determine a method for covering the administrative
392	392	4 costs of the program, which method may include a fee
393	393	5 imposed on each prescription pharmaceutical product sold
394	394	6 through the program or any other appropriate method as
395	395	7 determined by the Department, but the Department shall not
396	396	8 require a fee in an amount the Department determines would
397	397	9 significantly reduce consumer savings.
398	398	10 (e) Canadian suppliers and eligible importers
399	399	11 participating under the program:
400	400	12 (1) shall comply with the tracking and tracing
401	401	13 requirements of 21 U.S.C. 360; and
402	402	14 (2) shall not distribute, dispense, or sell
403	403	15 prescription drugs imported under the program outside of
404	404	16 the State.
405	405	17 (f) A participating eligible importer shall submit to the
406	406	18 vendor all of the following information about each drug to be
407	407	19 acquired by the importer under the program:
408	408	20 (1) the name and quantity of the active ingredient of
409	409	21 the drug;
410	410	22 (2) a description of the dosage form of the drug;
411	411	23 (3) the date on which the drug is received;
412	412	24 (4) the quantity of the drug that is received;
413	413	25 (5) the point of origin and destination of the drug;
414	414	26 and
415	415
416	416
417	417
418	418
419	419
420	420	HB3490 - 11 - LRB103 27325 CPF 53696 b
421	421
422	422
423	423	HB3490- 12 -LRB103 27325 CPF 53696 b HB3490 - 12 - LRB103 27325 CPF 53696 b
424	424	HB3490 - 12 - LRB103 27325 CPF 53696 b
425	425	1 (6) the price paid by the importer for the drug.
426	426	2 (g) A participating Canadian supplier shall submit to the
427	427	3 vender the following information about each drug to be
428	428	4 supplied by the Canadian supplier under the program:
429	429	5 (1) the original source of the drug, including:
430	430	6 (i) the name of the manufacturer of the drug;
431	431	7 (ii) the date on which the drug was manufactured;
432	432	8 and
433	433	9 (iii) the location including the country, state or
434	434	10 province, and city, where the drug was manufactured;
435	435	11 (2) the date on which the drug is shipped;
436	436	12 (3) the quantity of the drug that is shipped;
437	437	13 (4) the quantity of each lot of the drug originally
438	438	14 received and the source of the lot; and
439	439	15 (5) the lot or control number and the batch number
440	440	16 assigned to the drug by the manufacturer.
441	441	17 (h) The Department shall immediately suspend the
442	442	18 importation of a specific drug or the importation of drugs by a
443	443	19 specific eligible importer if it discovers that any drug or
444	444	20 activity is in violation of this Section or any federal or
445	445	21 State law or regulation. The Department may revoke the
446	446	22 suspension if, after conducting an investigation, it
447	447	23 determines that the public is adequately protected from
448	448	24 counterfeit or unsafe drugs being imported into this State.
449	449	25 Section 25. Federal approval.
450	450
451	451
452	452
453	453
454	454
455	455	HB3490 - 12 - LRB103 27325 CPF 53696 b
456	456
457	457
458	458	HB3490- 13 -LRB103 27325 CPF 53696 b HB3490 - 13 - LRB103 27325 CPF 53696 b
459	459	HB3490 - 13 - LRB103 27325 CPF 53696 b
460	460	1 (a) On or before September 1, 2023, the Department shall
461	461	2 submit a request to the United States Secretary of Health and
462	462	3 Human Services for approval of the program under 21 U.S.C.
463	463	4 384. The Department shall begin operating the program within 6
464	464	5 months after receiving such approval. The request must, at a
465	465	6 minimum:
466	466	7 (1) describe the Department's plan for operating the
467	467	8 program;
468	468	9 (2) demonstrate how the prescription drugs imported
469	469	10 into this State under the program will meet the applicable
470	470	11 federal and State standards for safety, effectiveness,
471	471	12 misbranding, and adulteration;
472	472	13 (3) include a list of proposed prescription drugs that
473	473	14 have the highest potential for cost savings to the State
474	474	15 through importation at the time that the request is
475	475	16 submitted;
476	476	17 (4) estimate the total cost savings attributable to
477	477	18 the program;
478	478	19 (5) include a list of potential Canadian suppliers
479	479	20 from which the State would import drugs and demonstrate
480	480	21 that the suppliers are in full compliance with relevant
481	481	22 Canadian federal and provincial laws and regulations.
482	482	23 (b) Notwithstanding any provision of this subsection to
483	483	24 the contrary, the Department may expend money for the purpose
484	484	25 of requesting approval of the program as described in
485	485	26 subsection (a), but the Department shall not spend any other
486	486
487	487
488	488
489	489
490	490
491	491	HB3490 - 13 - LRB103 27325 CPF 53696 b
492	492
493	493
494	494	HB3490- 14 -LRB103 27325 CPF 53696 b HB3490 - 14 - LRB103 27325 CPF 53696 b
495	495	HB3490 - 14 - LRB103 27325 CPF 53696 b
496	496	1 money to implement the program until the Department receives
497	497	2 approval of the program as described in subsection (a).
498	498	3 (c) Upon receipt of federal approval of the program, the
499	499	4 Department shall notify the President of the Senate and the
500	500	5 Speaker of the House of Representatives, as well as the Health
501	501	6 and Human Services Committee of the Senate and the Health and
502	502	7 Insurance Committee of the House of Representatives, or any
503	503	8 successor committees. After approval is received and before
504	504	9 the start of the next regular session of the General Assembly
505	505	10 in which the proposal could be funded, the Department shall
506	506	11 submit to all parties specified in this subsection a proposal
507	507	12 for program implementation and program funding.
508	508	13 Section 30. Reports. On or before December 1, 2024, and on
509	509	14 or before December 1 each year thereafter, the Department
510	510	15 shall submit a report to the Governor, the President of the
511	511	16 Senate, and the Speaker of the House of Representatives on the
512	512	17 operation of the program during the previous fiscal year. The
513	513	18 report must include, at a minimum:
514	514	19 (1) a list of the prescription drugs that were
515	515	20 imported under the program;
516	516	21 (2) the number of participating Canadian suppliers and
517	517	22 eligible importers;
518	518	23 (3) the number of prescriptions dispensed through the
519	519	24 program;
520	520	25 (4) the estimated cost savings during the previous
521	521
522	522
523	523
524	524
525	525
526	526	HB3490 - 14 - LRB103 27325 CPF 53696 b
527	527
528	528
529	529	HB3490- 15 -LRB103 27325 CPF 53696 b HB3490 - 15 - LRB103 27325 CPF 53696 b
530	530	HB3490 - 15 - LRB103 27325 CPF 53696 b
531	531	1 fiscal year and to date attributable to the program;
532	532	2 (5) a description of the methodology used to determine
533	533	3 which drugs should be included on the wholesale
534	534	4 prescription drug importation list; and
535	535	5 (6) documentation as to how the program ensures the
536	536	6 following that:
537	537	7 (i) Canadian suppliers participating in the
538	538	8 program are in full compliance with relevant Canadian
539	539	9 federal and provincial laws;
540	540	10 (ii) prescription drugs imported under the program
541	541	11 are not shipped, sold, or dispensed outside of this
542	542	12 State once in the possession of the eligible importer;
543	543	13 (iii) prescription drugs imported under the
544	544	14 program are pure, unadulterated, potent, and safe;
545	545	15 (iv) the program does not put consumers at a
546	546	16 higher health and safety risk than if the program did
547	547	17 not exist; and
548	548	18 (v) the program provides cost savings to the State
549	549	19 on imported prescription drugs.
550	550	20 Section 35. Importation program authorized; rulemaking.
551	551	21 (a) Upon approval by the Secretary, in accordance with
552	552	22 Section 30, the Department shall administer an importation
553	553	23 program.
554	554	24 (b) The Department shall approve a method of financing and
555	555	25 administrative costs of the importation program, which method
556	556
557	557
558	558
559	559
560	560
561	561	HB3490 - 15 - LRB103 27325 CPF 53696 b
562	562
563	563
564	564	HB3490- 16 -LRB103 27325 CPF 53696 b HB3490 - 16 - LRB103 27325 CPF 53696 b
565	565	HB3490 - 16 - LRB103 27325 CPF 53696 b
566	566	1 may include imposing a fee on each prescription pharmaceutical
567	567	2 product sold through the importation program or any other
568	568	3 appropriate method determined by the Department to finance
569	569	4 administrative costs. The Department shall not require a fee
570	570	5 in an amount that the Department determines would
571	571	6 significantly reduce consumer savings.
572	572	7 (c) The Department shall adopt rules necessary to
573	573	8 implement this Act.
574	574
575	575
576	576
577	577
578	578
579	579	HB3490 - 16 - LRB103 27325 CPF 53696 b